Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07039916 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 84 → 88 locationsv14
  2. Study sites: 83 to 84v13
  3. Study sites: 81 to 83v12
  4. Trial sites expanded: 75 → 81 locationsv11
  5. Study sites: 70 to 75v10
Show 8 earlier versionsHide 8 earlier versions
  1. Study sites: 58 to 70v9
  2. Study sites: 44 to 58v8
  3. Study sites: 32 to 44v7
  4. Study completion date: Dec 2027 to Dec 2028
    • Eligibility criteria revised
    • Study title revised
    v6
  5. Study sites: 25 to 32
    • Eligibility criteria shortened, about 1 word
    v5
  6. Study sites: 21 to 25v4
  7. Study sites: 14 to 21v3
  8. Study sites: 4 to 14v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
Trial Details
NCT Number NCT07039916
Lead Sponsor Immunovant Sciences GmbH
Conditions
(from sponsor)		 Generalized Myasthenia Gravis
Related terms Autoimmune Diseases, Myasthenia Gravis
Enrollment 231 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov